TY - JOUR
T1 - Attenuation of cisplatin-induced acute kidney injury by sanguinarine
T2 - modulation of oxidative stress, inflammation, and cellular damage
AU - Zaaba, Nur Elena
AU - Al-Salam, Suhail
AU - Beegam, Sumaya
AU - Elzaki, Ozaz
AU - Aldhaheri, Fatima
AU - Nemmar, Anas
AU - Ali, Badreldin H.
AU - Nemmar, Abderrahim
N1 - Publisher Copyright:
Copyright © 2025 Zaaba, Al-Salam, Beegam, Elzaki, Aldhaheri, Nemmar, Ali and Nemmar.
PY - 2025
Y1 - 2025
N2 - Introduction: Cisplatin (CP)-induced acute kidney injury (AKI) is a significant side effect of CP chemotherapy, driven by oxidative stress and inflammation. Sanguinarine (SANG), an alkaloid from the rhizomes of Sanguinaria canadensis and poppy-fumaria species, exhibits antioxidant and anti-inflammatory properties. This study examined SANG’s effect on CP-induced AKI in mice and its underlying mechanisms. Methods: Mice were orally administered 5 mg/kg SANG for 10 days. On the seventh day, they received a single intraperitoneal CP injection (20 mg/kg) and were sacrificed on the 11th day. Results: SANG significantly improved CP-induced decreases in body weight, water intake, urine volume, relative kidney weight, creatinine clearance, albumin-to-creatinine ratio, and plasma urea and creatinine levels. It also reduced elevated plasma neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, cystatin C, and adiponectin levels, as well as renal markers of inflammation and oxidative stress induced by CP administration. SANG normalized kidney mitochondrial dysfunction, DNA damage, and apoptosis caused by CP. It also inhibited the CP-induced increase in the expression of phosphorylated nuclear factor-κB and autophagy markers in the kidney. Histological analysis showed that SANG reduced acute tubular necrosis and intraluminal protein accumulation due to CP. Discussion: In conclusion, SANG mitigated CP-induced AKI by reducing inflammation, oxidative stress, DNA damage, apoptosis, and autophagy. Pending more comprehensive pharmacological and toxicological assessments, SANG may be regarded as a potential therapeutic agent for mitigating CP-induced AKI.
AB - Introduction: Cisplatin (CP)-induced acute kidney injury (AKI) is a significant side effect of CP chemotherapy, driven by oxidative stress and inflammation. Sanguinarine (SANG), an alkaloid from the rhizomes of Sanguinaria canadensis and poppy-fumaria species, exhibits antioxidant and anti-inflammatory properties. This study examined SANG’s effect on CP-induced AKI in mice and its underlying mechanisms. Methods: Mice were orally administered 5 mg/kg SANG for 10 days. On the seventh day, they received a single intraperitoneal CP injection (20 mg/kg) and were sacrificed on the 11th day. Results: SANG significantly improved CP-induced decreases in body weight, water intake, urine volume, relative kidney weight, creatinine clearance, albumin-to-creatinine ratio, and plasma urea and creatinine levels. It also reduced elevated plasma neutrophil gelatinase-associated lipocalin, kidney injury molecule-1, cystatin C, and adiponectin levels, as well as renal markers of inflammation and oxidative stress induced by CP administration. SANG normalized kidney mitochondrial dysfunction, DNA damage, and apoptosis caused by CP. It also inhibited the CP-induced increase in the expression of phosphorylated nuclear factor-κB and autophagy markers in the kidney. Histological analysis showed that SANG reduced acute tubular necrosis and intraluminal protein accumulation due to CP. Discussion: In conclusion, SANG mitigated CP-induced AKI by reducing inflammation, oxidative stress, DNA damage, apoptosis, and autophagy. Pending more comprehensive pharmacological and toxicological assessments, SANG may be regarded as a potential therapeutic agent for mitigating CP-induced AKI.
KW - apoptosis
KW - inflammation
KW - kidney injury
KW - mitochondrial dysfunction
KW - oxidative stress
KW - sanguinarine
UR - http://www.scopus.com/inward/record.url?scp=105002647850&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=105002647850&partnerID=8YFLogxK
U2 - 10.3389/fphar.2025.1567888
DO - 10.3389/fphar.2025.1567888
M3 - Article
AN - SCOPUS:105002647850
SN - 1663-9812
VL - 16
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
M1 - 1567888
ER -